BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29211870)

  • 1. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
    Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
    J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
    Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
    Lipplaa A; Dijkstra S; Gelderblom H
    Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
    Gossai N; Hilgers MV; Polgreen LE; Greengard EG
    Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
    Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.
    Rhou YJJ; Wang CJ; Nguyen M; Vanderniet JA; Munns CF; Coleman H; Kim J; Holmes-Walker DJ; Lim L; Girgis CM
    Calcif Tissue Int; 2022 Apr; 110(4):464-474. PubMed ID: 35088118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
    Boyce AM
    Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypercalcemia following denosumab treatment in a juvenile patient.
    Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
    J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K; Ramirez L; Kukreja K; Venkatramani R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm; Lee KH; Lee SH; Park W
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.